News

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Intuitive Surgical is a leader in surgical robotics, and the stock has a history of deep drawdowns.

Although the revenue and EPS for Intuitive Surgical (ISRG) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Moby summary of Intuitive Surgical, Inc.'s Q2 2026 earnings call

Intuitive Surgical (NASDAQ:ISRG) reported a solid second quarter of 2026, with management pointing to continued global adoption of its da Vinci, da Vinci SP and Ion platforms, even as U.S. procedure growth moderated and China remained challenging. Chief Executive Officer Dave Rosa said total proced

Intuitive Surgical (ISRG) delivered earnings and revenue surprises of +12.90% and +3.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical issued lackluster procedure guidance for the year on Thursday, leading the stock to take a dive.

Medical technology company Intuitive Surgical (NASDAQ:ISRG) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 18.5% year on year to $2.89 billion. Its non-GAAP profit of $2.80 per share was 11.9% above analysts’ consensus estimates. Stock drop is primarily driven by recent declines in overall surgery volumes, which were reported by major healthcare providers, as well as a recent Class II recall of certain da Vinci surgical components.

Wall Street is betting big on Ambarella's Physical AI opportunity.

Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.

In April 2026, Intuitive Surgical voluntarily initiated an ongoing Class II worldwide recall of certain da Vinci surgical system components after discovering an E-brake retainer pin issue that could impede emergency braking or cause uncontrolled column motion, with 454 affected units identified by specific serial numbers. This safety action, alongside growing attention on Intuitive’s AI-enabled da Vinci 5 rollout and competitive pressures in robotic surgery, raises fresh questions about how...

Today Earnings (a.m): UnitedHealth, GE Aerospace, U.S. Bancorp, Citizens Financial, Abbott Laboratories, State Street, Taiwan Semiconductor Manufacturing Earnings (p.m.): Netflix, Intuitive Surgical Economic data: Weekly jobless claims, Philadelphia Fed business-outlook survey, retail sales, pending home sales index, business inventories Fed speakers: Fed Vice Chair Philip Jefferson is expected to speak, as is Dallas Fed President Lorie Logan.

Intuitive Surgical's powerful growth is running headlong into some serious market challenges, and how management framed the collision tells you everything about the real risks.

Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc litigation remaining the key risk to watch.

ISRG is countering rising global robotic surgery competition with tiered platforms, AI features and a broad ecosystem focused on value over price.

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the 8 Worst Blue Chip Stocks to Buy Now. On July 9, 2026, BMO Capital analyst Vik Chopra initiated coverage of Intuitive Surgical, Inc. (NASDAQ:ISRG) with an Outperform rating and $518 price target. Chopra said the da Vinci 5 upgrade cycle remains in the early innings, procedure growth […]

The robotic surgery company has posted earnings beats in its past four quarters. Can it make it five in a row?

Johnson & Johnson stock dipped early Wednesday, though the healthcare giant beat second-quarter forecasts and raised its outlook.

Johnson & Johnson raised its full-year guidance on the back of better-than-expected second-quarter earnings as strength in its oncology portfolio helped offset falling sales for its former blockbuster drug, Stelara. The drugmaker on Wednesday reported adjusted earnings of $2.90 a share, beating the $2.85 a share analysts had anticipated. J&J logged $25 billion in sales, in line with Wall Street estimates and up 6% from the same period last year.

And Goldman Sachs may be right.

Medical technology company Intuitive Surgical (NASDAQ:ISRG) will be reporting results this Thursday afternoon. Here’s what investors should know.

Today Earnings: Johnson & Johnson, Morgan Stanley, BlackRock, PNC Financial Services, Conagra, Cintas, United Airlines, Bank of New York Mellon, Elevance Health, J.B. Hunt, ASML Economic data: Producer-price index data for June, Empire State manufacturing survey, EIA weekly petroleum status report, Fed beige book.

Intuitive Surgical's stock has fallen sharply in 2026, but that is more a function of investor sentiment than of the company.

Intuitive Surgical stock tumbled Tuesday after HCA Healthcare trimmed its full-year earnings outlook, noting a drop in surgeries.

Here is a way to get paid a meaningful income now on your Intuitive Surgical shares, cash you keep no matter what, in exchange for capping your gains at a price above today's.

Intuitive Surgical heads into Q2 earnings with strong procedure momentum, da Vinci 5 adoption and expectations for another earnings beat despite margin pressures.

This is a product-cycle year for Intuitive Surgical. The company's growth is fueled by hospitals and surgeons adopting its new da Vinci 5 and existing Ion robotic systems.

ISRG, IDXX and ALC are three AI-driven medical device laggards with strong business momentum and improving earnings estimates for a potential 2H rebound.

Intuitive Surgical (NASDAQ:ISRG) looks compelling ahead of its July 16 earnings report, and the setup rarely gets this clean for a category leader trading well below fair value. Shares sit at $413.58, down 26.71% YTD, while the 247 base-case target of $559.79 implies 35.35% upside. Wall Street sits higher still at $563.35, with 22 buy ... Intuitive Surgical Has +35% Upside: A Compelling Buy Story Before July 16

Intuitive Surgical stock has returned 28.4% over the past five years, yet its current checks point to a company that is not clearly cheap, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model sitting close to the market price while earnings based multiples lean expensive. Over five years, a 28.4% share price gain suggests Intuitive Surgical has rewarded patient holders, even though shorter term returns have been weaker. Growth expectations tied to expanding robotic...